write essay my town help me write a white paper reseach propsal services a review of literature business plan writing software free example of a lab report for biology research paper writing services reviews online sql training fashion essay help research paper topics sociology
Skip to main content

Active emulgels for controlled zero-order drug release

Ref-Nr: TA-B79089


Kurzfassung

·       Platform for zero-order (linear) drug-release

·       Constant, tunable release of hydrophobic drugs

·       3 components, economical and straightforward


Hintergrund

Releasing drugs with zero-order (constant release) is one of the ultimate goals of controlled drug-delivery vehicles. When drugs are released with zero-order, one can accurately control the drug plasma concentrations for a prolonged time.  Particularly, hydrophobic drugs (e.g., BCS class II drugs) are difficult to deliver at constant therapeutic levels due to their low bioavailability. As a hybrid of emulsion and hydrogel, emulgels have shown to improve solubility of hydrophobic drugs. However, delivery via existing emulgels is hampered by non-linear drug-release (first-order kinetics), resulting in the risk of under- or overdose of medication.


Bilder & Videos


Lösung

The innovation is a combination of a hydrogel and emulsion that release hydrophobic drugs at a constant rate. Component one is a standard polysaccharide based hydrogel that acts as a gelling agent ensuring the platform behaves like a solid. Critically, component two is the inventively ‘active’ emulsion that releases drugs at a constant, yet tunable, rate. The resulting ‘active emulgel’ has the potential to improve patient compliance by reducing the frequency of drug administration. Furthermore, next to BCS II class drugs, the platform allows incorporation of small peptides and modified DNA or RNA strands, thus expanding its scope as drug-delivery platform. With only three ingredients, the platform is economical, predictable, versatile and straightforward.


Vorteile

For oral drug uptake via encapsulated emulgels, in dermal applications or as wound dressing.


Bayerische Patentallianz GmbH


089 5480177-0
kontakt@baypat.de
www.baypat.de
Adresse
Destouchesstr. 68
80796 München



Entwicklungsstand

Machbarkeit


Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsführerin)

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen